---
title: An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells
  targeting CD80/86-upregulated DLBCL
date: '2024-02-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38340727/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240211170645&v=2.18.0
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric antigen receptor T cell (CAR T) therapy is a potent treatment
  for relapsed/refractory (r/r) B cell lymphomas but provides lasting remissions in
  only ∼40% of patients and is associated with serious adverse events. We identify
  an upregulation of CD80 and/or CD86 in tumor tissue of (r/r) diffuse large B cell
  lymphoma (DLBCL) patients treated with tisagenlecleucel. This finding leads to the
  development of the CAR/CCR (chimeric checkpoint receptor) design, which consists
  of a ...
disable_comments: true
---
Chimeric antigen receptor T cell (CAR T) therapy is a potent treatment for relapsed/refractory (r/r) B cell lymphomas but provides lasting remissions in only ∼40% of patients and is associated with serious adverse events. We identify an upregulation of CD80 and/or CD86 in tumor tissue of (r/r) diffuse large B cell lymphoma (DLBCL) patients treated with tisagenlecleucel. This finding leads to the development of the CAR/CCR (chimeric checkpoint receptor) design, which consists of a ...